Primavera Capital Group is a china-based investment firm, focusing on private equity and special situations opportunities.
Business Model:
Revenue: $185.4M
Employees: 51-200
Address: No.1 Jian Guo Men Wai Avenue
City: Beijing
State: beijing municipality
Zip: 100004
Country: CN
Primavera Capital Group is a China-based global investment firm. With offices located in Beijing and Hong Kong, Primavera manages both RMB and USD funds for leading institutions, corporations, and families in China and around the world. Primavera Capital Group was founded by Dr. Fred Hu, a renowned economist and successful investor, and a former partner and Chairman of Greater China at Goldman Sachs Group. The firm currently has 30+ investment professionals with an outstanding track record. The team combines global capital market experience, deep industry knowledge, and a unique network of relationships with policy-makers and regulators as well as leading CEOs and entrepreneurs in the region and globally. Primavera Capital Group puts great emphasis on rigorous fundamental research. The firm undertakes sophisticated analysis on economies, industries and companies to generate investment ideas, identify attractive opportunities, and guide its investment decisions. Primavera Capital Group employs a flexible investment strategy of growth capital, buy-out and control, and special situations - restructuring, distressed, and turn-arounds, etc.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
1/22/2021
Ticker Symbol:
PV.U
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2017 | Koubei | Private Equity Round | 1.1B |
10/2018 | ByteDance | Equity | 3B |
2/2022 | Adden Energy | Seed Round | 5.2M |
7/2021 | OptoMedic | Series D | - |
9/2021 | Accession Therapeutics Limited | Seed Round | - |
8/2022 | Enflame | Series C | - |
10/2019 | Danke Apartment | Series D | 190M |
6/2020 | Xingsheng Youxuan | Corporate Round | - |
3/2022 | Hex Trust | Series B | 0 |
7/2017 | Dashu Finance | Series C | 118M |
4/2016 | Ant Group | Series B | 0 |
4/2019 | Onion Math | Series D | 44.7M |
3/2016 | Cainiao Logistics | Series A | 1.5B |
5/2021 | Analytical Biosciences | Series A | - |
10/2021 | Ruigu | Series D | 250M |
6/2022 | Project Twelve | Seed Round | 8M |
2/2019 | Danke Apartment | Series C | 500M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
12/2021 | Xbiome | Series B | 0 |
1/2021 | Enflame | Series C | 278.8M |
1/2021 | 4Paradigm | Series D | 0 |
5/2018 | Souche | Series F | 578M |
5/2022 | Starna Therapeutics | Series A | 0 |
11/2022 | Subtle Medical | Series B | 25M |
11/2017 | WorldStrides | Private Equity Round | - |
5/2022 | Trash Warrior | Series A | 0 |
12/2021 | SyMap Medical | Series E | 100M |
5/2021 | Jenscare Biotech | Venture Round | - |
8/2019 | Ubox | Corporate Round | 225.5M |
11/2020 | Deepinfar Ocean Technology | Series B | 0 |
11/2019 | LBX Pharmacy | Post-IPO Secondary | 557M |
1/2020 | Zap Surgical Systems | Private Equity Round | 0 |
12/2018 | Lu.com | Series C | 0 |
8/2022 | Pingxin Technology | Series A | - |
10/2021 | GoTo Group | Private Equity Round | 0 |
2/2022 | Hong Kong Asia Heart Centre | Series D | 0 |
8/2018 | Xpeng Motors | Series B | 584.5M |
11/2017 | Souche | Series E | 335M |
1/2022 | Starfield Food &a; Science Technology | Series B | 0 |
12/2018 | Hello TransTech | Series G | 581.5M |
6/2021 | Trash Warrior | Seed Round | 1.5M |
5/2022 | Dimension | Seed Round | 8M |
11/2019 | Shijiazhuang Junlebao Dairy | Funding Round | 569.1M |
11/2020 | Xbiome | Funding Round | - |
3/2022 | Robotphoenix | Series D | 0 |
2/2021 | Xingsheng Youxuan | Series D | 0 |
8/2021 | Shukun Technology | Series D | 105.8M |
1/2023 | Blackpanda | Series A | 15M |
10/2021 | Love, Bonito | Series C | 0 |
3/2012 | Xunlei | Series E | 50M |
10/2021 | Envision Group | Private Equity Round | 1B |
9/2016 | Yum! China | Private Equity Round | 460M |
7/2018 | Zuoyebang | Series D | 350M |
11/2022 | Accession Therapeutics | Series A | 0 |
5/2021 | Beisen | Series F | 0 |
11/2018 | Alibaba Bendi Shenghuo Fuwu Gongsi | Funding Round | 4B |
12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
7/2017 | Moviebook | Series C | 73.8M |
8/2022 | Pingxin Technology | Series A | - |
6/2022 | Project Twelve | Seed Round | 0 |
5/2022 | Trash Warrior | Series A | 0 |
5/2022 | Starna Therapeutics | Series A | 0 |
3/2022 | Hex Trust | Series B | 0 |
3/2022 | Robotphoenix | Series D | 0 |
2/2022 | Hong Kong Asia Heart Centre | Series D | 0 |
1/2022 | Starfield Food &a; Science Technology | Series B | 0 |
12/2021 | Xbiome | Series B | 0 |
12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|